IDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024. In the quarter to June 2026, revenue grew 125.8%, EPS fell 38.6% and free cash flow fell 41.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow IDYA
IDEAYA Biosciences, Inc. (IDYA) EV/Sales
As of 16 October 2026, IDEAYA Biosciences, Inc. (IDYA) trades at a EV/Sales of 9.4×. Over the past ten years it has ranged from 0.0× (June 2021) to 114× (July 2024); the current reading is higher than 48% of that period. That is in line with the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.5× | (82.76%) |
| FY2024 | 60.8× | (5.19%) |
| FY2023 | 64.2× | 819.46% |
| FY2022 | 7.0× | (66.75%) |
| FY2021 | 21.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 11.1× | 11.52% |
| Mar 2026 | 10.0× | (4.98%) |
| Dec 2025 | 10.5× | 44.43% |
| Sep 2025 | 7.3× | (88.68%) |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | n/m |
| VKTX Viking Therapeutics, Inc. compare | n/m |
| CELC Celcuity, Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. compare | 2.0× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 4.3× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 7.8× |
| DNLI Denali Therapeutics Inc. compare | 8.6× |
| IDYA IDEAYA Biosciences, Inc. | 9.4× |
| XENE Xenon Pharmaceuticals Inc. compare | 144× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)